The 2023 winners and losers list: Who was up and who was down in biopharma

I hate end-of-the-year pieces. They tend to be dull and as­signed by some ed­i­tor who sees the odome­ter rolling over and thinks that’s more in­ter­est­ing than ac­tu­al news.

But part of the gig at End­points News is keep­ing tabs on who’s ⬆️ and who’s ⬇️, which strate­gies and mech­a­nisms are pay­ing off (and which are fail­ing), and what it says about the fu­ture for the com­pa­nies, ideas, mol­e­cules, in­vest­ments and peo­ple we fol­low every day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.